Pamela A. Trail

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates

Pamela A. Trail, David Willner, Shirley J. Lasch et al. · Science · 1993 · 550 citations

Tumor Biology, Cancer Immunosurveillance, Lewis Y +13

Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates:  Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity

Gene M. Dubowchik, Raymond A. Firestone, Linda Padilla et al. · Bioconjugate Chemistry · 2002 · 535 citations

Immunocytochemical Technique, Glycobiology, Immunology +20

Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

Lila Adnane, Pamela A. Trail, I Taylor et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 2006 · 463 citations

Medicine, Receptor Tyrosine Kinase, Pharmacology +8

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 462 citations

Oncology, Medicine, Tumor Growth +10